Tony Sk Mok
Overview
Explore the profile of Tony Sk Mok including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
218
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lee J, Tsuboi M, Kim E, Mok T, Garrido P
Future Oncol
. 2022 Aug;
18(27):3085-3100.
PMID: 36004638
Inflammation in the tumor microenvironment is a complicit and known carcinogenesis driver. Inhibition of IL-1β, one of the most abundant and influential cytokines in the tumor microenvironment, may enhance the...
2.
West H, McCleland M, Cappuzzo F, Reck M, Mok T, Jotte R, et al.
J Immunother Cancer
. 2022 Feb;
10(2).
PMID: 35190375
Background: The efficacy of atezolizumab (A) and/or bevacizumab (B) with carboplatin/paclitaxel (CP) chemotherapy was explored in the phase III, randomized IMpower150 study in patients with non-squamous non-small cell lung cancer...
3.
Garrido P, Pujol J, Kim E, Lee J, Tsuboi M, Gomez-Rueda A, et al.
Future Oncol
. 2021 Mar;
17(12):1459-1472.
PMID: 33648347
Canakinumab is a human IgGκ monoclonal antibody, with high affinity and specificity for IL-1β. The Canakinumab Anti-Inflammatory Thrombosis Outcome Study (CANTOS) trial, evaluating canakinumab for cardiovascular disease, provided the first...
4.
Li L, Li C, Mao H, Du Z, Chan W, Murray P, et al.
Sci Rep
. 2016 Oct;
6:34435.
PMID: 27708339
No abstract available.
5.
Li L, Li C, Mao H, Du Z, Chan W, Murray P, et al.
Sci Rep
. 2016 May;
6:26591.
PMID: 27225590
Promoter CpG methylation is a fundamental regulatory process of gene expression. TET proteins are active CpG demethylases converting 5-methylcytosine to 5-hydroxymethylcytosine, with loss of 5 hmC as an epigenetic hallmark...
6.
Ma B, Hui E, Mok T
Lancet Oncol
. 2010 Feb;
11(1):75-84.
PMID: 20129130
Population-based differences in toxicity and clinical outcome following treatment with anticancer drugs have an important effect on oncology practice and drug development. These differences arise from complex interactions between biological...